Schizophrenia & Other Psychotic Disorders
Conference Coverage
Will paying patients to take oral antipsychotics boost adherence?
COPENHAGEN – Economic incentives have been shown to improve adherence to long-acting injectable antipsychotics.
From the Journals
Resting-state cerebral blood flow tied to apathy in schizophrenia
“The paucity of reported associations between striatal rCBF and negative symptoms could result from the fact that until now apathy and diminished...
From the Journals
COGS update shows viability of endophenotypes in schizophrenia research
"As stable biomarkers of the underlying brain dysfunctions, endophenotypes hold promise for parsing clinical heterogeneity of schizophrenia and...
Commentary
Should psychiatrists prescribe nonpsychotropic medications?
In certain scenarios, prescribing a nonpsychotropic medication is the logical choice.
Commentary
‘Joker’ filled with mental illness misconceptions
Dr. Susan Hatters Friedman and Dr. Karen B. Rosenbaum say unrealistic portrayals of the link between mental illness, violence, and forensic...
Conference Coverage
Spotlight is on promising investigational antipsychotics
COPENHAGEN – The focus is on the unmet need for better treatments for negative symptoms of schizophrenia.
Commentary
Will changing the names of psychiatric medications lead to better treatment?
Dr. Robert T. London wonders whether the new Neuroscience-based Nomenclature Project will be good for patient care.
Commentary
Psychodiagnostic testing services: The elusive quest for clinicians
Imagine the clinical care consequences if patients seen in specialty or primary care practices did not have ready access to laboratory, other...
Conference Coverage
Agitation in psychosis: Still no ‘magic bullet’
SAN DIEGO – Some evidence supports various treatments, including antipsychotics, Dr. Marc Agronin said.
FDA/CDC
FDA approves transdermal asenapine system for schizophrenia
This approval marks the first transdermal patch formulation of an antipsychotic for treatment of schizophrenia.
From the Journals
Schizophrenia patients have ‘aberrant’ response to Epstein-Barr
Individuals with schizophrenia appear to express atypical proportions of antibodies to the virus.